Selexys Pharmaceuticals, Corp., is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of inflammation, thrombosis and metastasis across a broad range of severe diseases. Selexys is also developing an antibody directed against PSGL-1 for the treatment of Crohn's disease, multiple myeloma, and other inflammatory disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/19/12 | $23,000,000 | Series A |
MPM Capital | undisclosed |
